Baudax Bio, Inc. (BXRX)


-0.04 (-11.34%)
Symbol BXRX
Price $0.3103
Beta 2.055
Volume Avg. 3.03M
Market Cap 2.848M
Shares () -
52 Week Range 0.3-12.24
1y Target Est -
DCF Unlevered BXRX DCF ->
DCF Levered BXRX LDCF ->
ROE 359.40% Strong Buy
ROA -260.39% Strong Sell
Operating Margin -
Debt / Equity -82.13%
P/E -
P/B -0.14 Neutral


Consensus EPS

Upgrades & Downgrades

Latest BXRX news

Dr. Geraldine A. Henwood Ph.D.
NASDAQ Capital Market

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.